The clinical implications of cytochrome P450 interactions with opioids and strategies for pain management

Journal of Pain and Symptom Management

Volumn 44, Issue 6 SUPPL., 2012, Pages

  Brennan, Michael J ^a  

^a The Pain Center of Fairfield   (United States)

Author keywords

Adverse drug reactions; cytochrome P450; drug drug interactions; extensive metabolizers; genetic polymorphisms; intermediate metabolizers; metabolism; opioids; pharmacokinetics; poor metabolizers; ultrarapid metabolizers

Indexed keywords

BERGAMOTTIN; CEFTRIAXONE; CLARITHROMYCIN; CODEINE; CYTOCHROME P450; DIAZEPAM; FENTANYL; FLUOXETINE; GABAPENTIN; ITRACONAZOLE; KETOCONAZOLE; METFORMIN; METHADONE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; NALOXONE; NEFAZODONE; NELFINAVIR; OPIATE; OXYCODONE; RITONAVIR; SIMVASTATIN; TRAZODONE; TROLEANDOMYCIN; VALPROIC ACID; VORICONAZOLE;

ANALGESIA; ARTICLE; BACKACHE; COMORBIDITY; CONTINUOUS INFUSION; COUGHING; DEPRESSION; DRUG INHIBITION; DRUG METABOLISM; DRUG RELEASE; HELICOBACTER INFECTION; HUMAN; NECK PAIN; PNEUMONIA; POSTTRAUMATIC STRESS DISORDER; RESPIRATION DEPRESSION; TONIC CLONIC SEIZURE;

ANALGESICS, OPIOID; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; LIVER; MODELS, BIOLOGICAL; OPIOID-RELATED DISORDERS; PAIN;

EID: 84870946229     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2012.08.012     Document Type: Article

References (25)

1. C.E. Argoff, and L.M. Yanni Pharmacogenetics and pain Prim Care Q 2010 1 8
2. H.S. Smith Opioid metabolism Mayo Clin Proc 84 2009 613 624
3. G.W. Pasternak Molecular insights into mu opioid pharmacology: from the clinic to the bench Clin J Pain 26 Suppl 10 2010 S3 S9
4. D.A. Fishbain, D. Fishbain, and J. Lewis Genetic testing for enzymes of drug metabolism: does it have clinical utility for pain medicine at the present time? A structured review Pain Med 5 2004 81 93
5. F. Tennant Genetic screening for defects in opioid metabolism: historical characteristics and blood levels Pract Pain Manag 11 2011 1 2
6. S.F. Zhou Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I Clin Pharmacokinet 48 2009 689 723
7. U.M. Stamer, and F. Stüber Genetic factors in pain and its treatment Curr Opin Anaesthesiol 20 2007 478 484
8. L. Bertilsson Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects Clin Pharmacol Ther 82 2007 606 609
9. G. Ruaño, G. Makowski, and A. Windemuth High carrier prevalence of deficient and null alleles of CYP2 genes in a major USA hospital: implications for personalized drug safety Per Med 3 2006 131 137
10. J. Lötsch, C. Skarke, J. Liefhold, and G. Geisslinger Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives Clin Pharmacokinet 43 2004 983 1013
11. T.N. Andreassen, P. Klepstad, and A. Davies Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients Eur J Clin Pharmacol 67 2011 493 506
12. M. Adams, H.J. Pieniaszek Jr., A.R. Gammaitoni, and H. Ahdieh Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways J Clin Pharmacol 45 2005 337 345
13. J. Lötsch, and G. Geisslinger Current evidence for a genetic modulation of the response to analgesics Pain 121 2006 1 5
14. S.F. Zhou, C.C. Xue, X.Q. Yu, C. Li, and G. Wang Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring Ther Drug Monit 29 2007 687 710
15. American Society of Health-System Pharmacists Top patient concerns 2002 omnibus survey results 2002 ASHP Bethesda, MD
16. Forum on Drug Discovery, Development, and Translation, J.M. Drazen, J. Rainey, H. Begg, and A.S. Butler Adverse drug event reporting: The roles of consumers and health care professionals. Workshop summary 2007 The National Academies Press Washington, DC
17. D.L. Gourlay, H.A. Heit, and Y.H. Caplan Urine drug testing in clinical practice: The art and science of patient care 2010 PharmaCom Group, Inc. Stamford, CT
18. Y. Gasche, Y. Daali, and M. Fathi Codeine intoxication associated with ultrarapid CYP2D6 metabolism N Engl J Med 351 2004 2827 2831
19. G. Andersen, L. Christrup, and P. Sjogren Relationships among morphine metabolism, pain and side effects during long-term treatment: an update J Pain Symptom Manage 25 2003 74 91
20. P. Madadi, D. Hildebrandt, and I.Y. Gong Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions Pediatrics 126 2010 e986 e989
21. D.A. Fishbain, J.E. Lewis, and J. Gao Allegations of medical malpractice in chronic opioid analgesic therapy possibly related to collaborative/split treatment and the P-450 enzyme system: forensic case report Pain Med 11 2010 1419 1425
22. J. Wahawisan, S. Kolluru, T. Nguyen, C. Molina, and J. Speake Methadone toxicity due to smoking cessation - a case report on the drug-drug interaction involving cytochrome P450 isoenzyme 1A2 Ann Pharmacother 45 2011 e34
23. R. Horton, and C. Barber Opioid-induced respiratory depression resulting from transdermal fentanyl-clarithromycin drug interaction in a patient with advanced COPD J Pain Symptom Manage 37 2009 e2 e5
24. B. Girennavar, G.K. Jayaprakasha, and B.S. Patil Potent inhibition of human cytochrome P450 3A4, 2D6, and 2C9 isoenzymes by grapefruit juice and its furocoumarins J Food Sci 72 2007 C417 C421
25. C.F. Samer, Y. Daali, and M. Wagner The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone Br J Pharmacol 160 2010 907 918